HID- cổ phiếu năng lượng xanh, đồng hành phát triển bền vững.

Chúc mừng các cổ đông mới lên tàu hôm qua.

Ráng lên 3 khấc nữa thì đẹp hơn

Các cụ nhớ đảm bảo ngồi cách nhau 2m nhá
Chủ top có bán khẩu trang và nước sát khuẩn ko? lên tày này bán nhiều khách quá kìa

Đẹp nhất là HID lên 3 còn LIG đứng

Lig lên 3 rùi

Sao lại trù dập nhau thế

Đang ngậm đắng lcg đây

Ngành nghề na ná, xem ra HID nổi tiếng hơn LIG

--- Gộp bài viết, May 5, 2020, Bài cũ: May 5, 2020 ---

Hehe thấy cụ thớt có ý nhảy tàu qua LIG

--- Gộp bài viết, May 5, 2020 ---

Mới vớt, mai cụ

Giao nhiệm vụ nặng nề quá

https://www.nytimes.com/2020/05/05/health/pfizer-vaccine-coronavirus.html
Pfizer Begins Human Trials of Possible Coronavirus Vaccine
The drug company, along with a German partner, is running tests in healthy volunteers. It’s one of several companies on an accelerated timetable to try to find a safe, effective vaccine.





A volunteer taking part in a human trial of a potential vaccine for the coronavirus. Nearly a dozen groups have started testing potential vaccines in human trials. Credit...Oxford University, via Associated Press

By Knvul Sheikh

• May 5, 2020, 6:45 a.m. ET

Pfizer and the German pharmaceutical company BioNTech announced that their potential coronavirus vaccine began human trials in the United States on Monday. If the tests are successful, the vaccine could be ready for emergency use here as early as September.

The two firms are jointly developing a vaccine candidate based on genetic material known as messenger RNA, which carries the instructions for cells to make proteins. By injecting a specially designed messenger RNA into the body, the vaccine could potentially tell cells how to make the spike protein of the coronavirus without actually making a person sick.

Because the virus typically uses this protein as a key to unlock and take over lung cells, the vaccine could train a healthy immune system to produce antibodies to fight off an infection. The technology also has the advantage of being faster to produce, and tends to be more stable than traditional vaccines, which use weakened virus strains.

Moderna, Inovio, CanSino and several other pharmaceutical companies are trying similar approaches, some of which began the first phase of tests in humans a few weeks ago. But no vaccine made with this technology for other viruses has ever reached the global market.

ADVERTISEMENT